The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors.
Strand
Vibeke
V
Hochberg
Marc C
MC
D000368:Aged; D000068579:Celecoxib; D003328:Coronary Thrombosis / Q000139:chemically induced* / Q000401:mortality; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D008297:Male; D011720:Pyrazoles; D016032:Randomized Controlled Trials as Topic; D013449:Sulfonamides / Q000009:adverse effects*; D013450:Sulfones; D015996:Survival Rate
D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D000068579:Celecoxib